Ladenburg Thalmann analyst Aydin Huseynov downgraded Spruce Biosciences, Inc. (NASDAQ: SPRB) from Buy to Neutral.The analyst comments "Yesterday, SPRB announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Spruce Biosciences, Inc. (SPRB) PT Lowered to $4 at OppenheimerMarch 14, 2024 9:11 AM H.C. Wainwright Downgrades Spruce Biosciences, Inc. (SPRB) to NeutralMarch 14, 2024 8:07 AM Guggenheim Downgrades Spruce Biosciences, Inc. (SPRB) to NeutralMarch 14, 2024 7:13 AM Leerink Partners Downgrades Spruce Biosciences, Inc. (SPRB) to Market PerformMarch 14, 2024 6:19 AM Spruce Biosciences, Inc. (SPRB) PT Lowered to $3 at JMP Securities, 'We wanted to see a clean safety profile'March 14, 2024 2:40 AM RBC Capital Downgrades Spruce Biosciences, Inc. (SPRB) to Sector Perform, 'Trial Miss Puts Tilda’ Future in Flux'March 13, 2024 9:50 PM After-hours movers: UiPath, SentinelOne, Under Armour, and moreMarch 13, 2024 4:42 PM Form 8-K SPRUCE BIOSCIENCES, INC. For: Mar 10March 13, 2024 4:13 PM Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 13, 2024 4:08 PM Spruce Biosciences (SPRB) Halted, News PendingMarch 13, 2024 4:02 PM Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-203March 13, 2024 4:01 PM Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAHMarch 13, 2024 4:01 PM